Author

Patient number

Follow-up (yr)

Dose (Gy)

Progression-free survival  10 yr (%)

Overall survival 10 yr (%)

Visual Improvement (%)

Endocrine Dysfunction (%)

Bataini (15)

57

7.5

51.7

80

83.5

55

37

Tao (28)

29

10

54

100

89

81

72

Horwich (12)

30

10

45-50

90

93

43

33

Jenkin (5 )

38

50

73

79

13

nr

Pierce ( 9 )

24

6

54

88

100

30

73

Sung (21)

43

>5

35-60

79

56

49.5

11

Wong (22)

24

9.4

48

55

87

35

8

Debus (10)

10

5

52.4

90

100

30

1

Khafaga (13)

28

10

50

62

75

15

52

Combs (30)

15

8

52.2

72

90

40

7

Grabenbauer (29)

25

9

45-60

69

94

36

48